CClinicalTrials.gg
CompletedNCT01652378phMRIUpdated Sep 9, 2019

Pharmacologic MRI in Cocaine Addiction

An observational study in Cocaine Dependence, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 21 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-09.

Sponsored by University of Texas Southwestern Medical Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
12
Ages
21 Years to 64 Years
Sex
All
01

Study summary

In the proposed study, the investigators will assess the brain response to medication probes the investigators have previously studied with SPECT. The brain response to ondansetron and lidocaine infusions will be measured Arterial Spin Labeling and functional connectivity MRI (fcMRI).

Read the detailed description

An extensive effort has been mounted to understand the neurobiologic mechanisms involved in the development and persistence of cocaine addiction and tendency to relapse. Although the last two decades have resulted in an explosion in our understanding of the biological mechanisms of reward, establishing the relevance of this knowledge to the addictive process has been problematic. Most importantly, this information has been of limited utility in offering new pharmacologic treatment approaches to addicted patients - particularly those with cocaine addiction. Over the past 15 years our laboratory has published multiple studies using pharmacologic probes to explore the biologic underpinnings of cocaine addiction using single photon emissions computerized tomography (SPECT) technology. More recently, however, functional magnetic resonance imaging (fMRI) has offered several advantages over SPECT and is now a favored approach, e.g. fMRI allows the continuous measurement of neural responses rather than a very limited time period with SPECT (1-3 minutes every 48 hours). Using fMRI [including both ASL (Arterial Spin Labeling) and fcMRI (functional connectivity], the neural response can be measured throughout the 60 min that follows infusion, allowing identification and capture of the maximal brain response period that may occur at any time during this 60 min. In the proposed study, we will assess the brain response to two of the probes (scopolamine and lidocaine) we have previously studied with SPECT.

02

Conditions studied

  • Cocaine Dependence

Keywords

  • cocaine addiction
  • neuroimaging
  • functional magnetic resonance imaging (fMRI)
03

In context

Cocaine-Related Disorders

415 studies on the registry are indexed under Cocaine-Related Disorders; 12 are open to participants now.

This study's enrollment of 12 is below the median of 24 across 27 observational studies indexed under Cocaine-Related Disorders.

Browse Cocaine-Related Disorders studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 100 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects with cocaine addiction will be recruited from patients requesting treatment for addiction at the Dallas VA Medical Center and Homeward Bound,Inc. Recently using cocaine patients and healthy controls will be recruited from flyers and internet ads.

Inclusion criteria

  • Cocaine dependence (cocaine patients)
  • identify cocaine as their present primary drug of use
  • Patients must have used cocaine within the previous 4 weeks (by patient history) and be abstinent for at least 1 week.
  • No drug dependence (healthy control population).

Exclusion criteria

Exclusion Criteria:

  • Other medical or psychiatric disorders that may effect neural functioning.
  • Medications that may effect brain functioning
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
12 participants (actual)
Patient registry
No

Groups and cohorts

  • Cocaine-Addicted Participants

    Group of participants diagnosed with cocaine dependence

    Drug: ondansetron, lidocaine

  • Control Participants

    healthy control volunteers

    Drug: ondansetron, lidocaine

Interventions

  • Drugondansetron, lidocaine

    Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion. Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion).

    Also known as: Zofran, Xylocaine

06

What researchers measure

Primary outcomes

  1. blood-oxygen-level-dependent contrast (BOLD)

    change in BOLD response to drug infusion (ondansetron, lidocaine).

    Time frame: 60 minutes after drug infusion

07

Study locations

1 site
  • UT Southwestern Medical Center at Dallas, Divison on Addictions
    Dallas, Texas 75390, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01652378
Lead sponsor
University of Texas Southwestern Medical Center
Responsible party
Sponsor
First posted
Jul 30, 2012
Start date
Aug 2012
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Sep 9, 2019

Study contacts

Bryon Adinoff, M.D.
principal investigator · UT Southwestern Medical Center at Dallas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion